

University of Kentucky

UKnowledge

Graduate Center for Nutritional Sciences
Faculty Patents

Nutritional Sciences

4-5-2005

Method for Treating Cytokine Mediated Hepatic Injury

Peter R. Oeltgen

University of Kentucky, peter.oeltgen@uky.edu

Paul D. Bishop

Craig J. McClain

University of Kentucky

Shirish Barve

University of Kentucky

Follow this and additional works at: https://uknowledge.uky.edu/nutrisci_patents



Part of the [Medical Pharmacology Commons](#)

[Right click to open a feedback form in a new tab to let us know how this document benefits you.](#)

Recommended Citation

Oeltgen, Peter R.; Bishop, Paul D.; McClain, Craig J.; and Barve, Shirish, "Method for Treating Cytokine Mediated Hepatic Injury" (2005). *Graduate Center for Nutritional Sciences Faculty Patents*. 25.

https://uknowledge.uky.edu/nutrisci_patents/25

This Patent is brought to you for free and open access by the Nutritional Sciences at UKnowledge. It has been accepted for inclusion in Graduate Center for Nutritional Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.



US006875742B2

(12) **United States Patent**
Oeltgen et al.

(10) **Patent No.:** **US 6,875,742 B2**
(45) **Date of Patent:** **Apr. 5, 2005**

(54) **METHOD FOR TREATING CYTOKINE
MEDIATED HEPATIC INJURY**

(75) Inventors: **Peter R. Oeltgen**, Winchester, KY
(US); **Paul D. Bishop**, Fall City, WA
(US); **Craig J. McClain**, Lexington,
KY (US); **Shirish Barve**, Lexington,
KY (US)

(73) Assignees: **ZymoGenetics, Inc.**, Seattle, WA (US);
**University of Kentucky Research
Foundation**, Lexington, KY (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 182 days.

(21) Appl. No.: **09/971,902**

(22) Filed: **Oct. 5, 2001**

(65) **Prior Publication Data**

US 2002/0103124 A1 Aug. 1, 2002

Related U.S. Application Data

(60) Provisional application No. 60/238,991, filed on Oct. 10,
2000.

(51) **Int. Cl.**⁷ **A61K 38/10**; C07K 14/435

(52) **U.S. Cl.** **514/13**; 514/2; 514/893;
514/894; 514/937; 530/300; 530/302

(58) **Field of Search** 514/13.2, 893,
514/894, 937; 530/300, 302

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,656,420 A	8/1997	Chien	435/1.2
6,103,722 A	8/2000	Schultz et al.	514/249
6,380,164 B1 *	4/2002	Oeltgen et al.	514/16

FOREIGN PATENT DOCUMENTS

WO	WO99/56766	11/1999	A61K/38/08
----	------------	---------	-------	------------

OTHER PUBLICATIONS

Wu et al., *Delta opioid extends hypothermic preservation
time of the lung*, J. Thorac. Cardiovasc. Surg. 1996; 111:
259-267.

Zhao and Bhargava, *Effects of multiple intracerebroven-
tricular injections of [D-Pen2, D-Pen5] enkephalin and
[D-Ala2, Glu4] deltorphin II on tolerance to their analgesic
action and on brain δ -opioid receptors*, Brain Research: 745
(1997) 243-247.

Barra et al., *Deltorphan, a 17 amino acid opioid peptide from
the skin of the Brazilian hylid frog. Phyllomedusa burmeis-
teri*, Peptides (Tarrytown), vol. 15, No. 2, 1994, 199-202.

Bohlinger et al., *Interleukin-1 and nitric oxide protect
against tumor necrosis factor α -induced liver injury
through distinct pathways*, Hepatology, 22: 1829-1837,
1995.

Bolling et al., *The use of hibernation induction triggers for
cardiac transplant preservation*, Transplantation 63:
326-329, 1997.

Bolling et al., *Delta opioid agonist/antagonist activity and
ischemic tolerance*, American Heart Association Meeting,
Atlanta, GA, Nov., 1999.

House et al., *A comparative study of immunomodulation
produced by in vitro exposure to delta opioid receptor
agonist peptides*, Peptides, (1996) 17(1): 75-81.

Kevelaitis et al., *Opening of potassium channels: The com-
mon cardioprotective link between preconditioning and
natural hibernation?*, Circulation 99: 3079-3085, 1999.

Leist et al., *Activation of the 55 kDa TNF receptor is
necessary and sufficient for TNF-induced liver failure,
hepatocyte apoptosis, and nitrite release*, The Journal of
Immunology 154: 1307-1316, 1995.

Bolling et al., *Use of "natural" hibernation induction trig-
gers for myocardial protection*, Annals Thorac. Surg.:
623-627, 1997.

Bolling et al., *Hibernation triggers and myocardial protec-
tion*, Circulation 98: II-220 to II-1224, 1998.

Chien et al., *Two-day preservation of major organs with
autoperfusion multiorgan preparation and hibernation
induction trigger*, J. Thorac. Cardiovasc. Surg., 102:
224-234, 1991.

Chien et al., *Extension of tissue survival time in multiorgan
block preparation with a delta opioid DADLE ([D-Ala2,
D-Leu5]-enkephalin)*, J. Thorac. Cardiovasc. Surg., 107:
965-967, 1994.

Crain and Shen, *Antagonists of excitatory opioid receptor
functions enhance morphine's analgesic potency and
attenuate opioid tolerance/dependence liability*, Pain 84
(2000), 121-131.

Fryer et al., *Opioid-induced second window of cardiopro-
tection: Potential role of mitochondrial K-ATP channels*,
Circ Res. 1999; 84: 846-851.

Stefano et al., *Delta-2 opioid receptor subtype on human
vascular endothelium uncouples morphine stimulated nitric
oxide release*, International J. Cardiology 64: Suppl. 1,
S43-S51, 1998.

Thomas et al., *Structure-activity relationships of a series of
'D-Ala2-deltorphan I and II analogues: In vitro blood-
-brain barrier permeability and stability*, Journal of Phar-
macology and Experimental Therapy, vol. 281, No. 2:
817-825, 1997.

(Continued)

Primary Examiner—Janet Andres

Assistant Examiner—Fozia Hamud

(74) *Attorney, Agent, or Firm*—Wood, Herron & Evans,
L.L.P.

(57) **ABSTRACT**

A method of modulating cytokine mediated hepatic injury
by administering compound-D SEQ ID NO:1 to a mammal.
A concentration of the compound in the range of about 0.5
mg/kg to about 20 mg/kg in a physiologically acceptable
formulation blocks a cytokine cascade. A therapeutic
method of modulating cytokine mediated acute
inflammatory, trauma induced and toxin induced hepatic
injury, particularly via tumor necrosis factor modulation, is
thus disclosed.

9 Claims, No Drawings

OTHER PUBLICATIONS

- Thornton, Jr. et al., *Opioid peptides and primary biliary cirrhosis*, BMJ, vol. 297, No. 6662: 1501-4, 1988.
- Schultz et al., *Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts*, Am. J. Physiol. 268 (Heart Circ. Physiol. 3): H2157-H2161, 1995.
- Schulz et al., *Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine*, Am. J. Physiol. 267: H1341-1352, 1994.
- Schwartz et al., *Delta opioid receptors and low temperature myocardial protection*, Ann. Thorac. Surg. 68: 2089-92, 1999.
- Root et al., "Septicemia and septic shock", Part Five of Infectious Diseases, Section 3, Clinical Syndromes, *Harrison's Principles of Internal Medicine*, 12th Ed., McGraw-Hill, 1991, 502-507.
- Schultz et al., *Ischemic preconditioning in the intact rat heart is mediated by δ 1- but not μ or κ -opioid receptors*, Circ 97: 1282-1289, 1998.
- Schultz et al., *Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart*, Circ. Research. 78: 1100-1104, 1996.
- Maslov and Lishmanov, *Effects of μ - and delta opioid receptor ligands on rhythm and contractility disorders of isolated rat heart in postischemic period*, Kardiologiya 1998; 12: 25-30 (Russian w/ English translation).
- Mayfield and D'Alecy, *Delta-1 opioid receptor dependence of acute hypoxic adaptation*, J. Pharmacol. Exp. Ther. 268: 74-77, 1994.
- Morgan, *Regulation of human B lymphocyte activation by opioid peptide hormones: Inhibition of IgG production by opioid receptor class (gamma-kappa-, and delta) selective agonists*, Journal of Neuroimmunology, vol. 65, No. 1: 21-30, 1996.
- Oeltgen et al., *The use of delta-2 opioid agonists for myocardial ischemia protection*, Abstract, Experimental Biology 2000, submitted Nov., 1999.
- Oeltgen et al., *Extended lung preservation with the use of hibernation trigger factors*, Ann. Thorac. Surg. 61: 1488-93, 1996.
- Reisine et al., *Opioid analgesics and antagonists*, Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 9th Ed., 1995, Section III Drugs Acting on the Central Nervous System, 23: 521-554.
- Toombs et al., *Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide*, Cardio. Res. 27: 617-622, 1993.
- Tsutsui et al., *IL-18 accounts for both TNF- α - and fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice*, The Journal of Immunology, 159: 3961-3967, 1997.
- VanWinkle et al., *Cardioprotection provided by adenosine receptor activation is abolished by blockade of the K-ATP channel*, Am. J. Physiol. 266: H829-H839, 1994.
- Leist et al., *Murine hepatocyte apoptosis induced in vitro and in vivo by TNF- α requires transcriptional arrest*, The Journal of Immunology, 153: 1778-1788, 1994.
- Lishmanov et al., *Activation of the μ -opioid receptors as a factor increasing heart resistance against ischemic and reperfusion damages*, Russian J. Physiol. 1998; 84 (11) (Russian w/ attached English translation).
- Malaguarnera et al., *Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus*, Journal of Gastroenterology, 32: 211-215, 1997.

* cited by examiner

1

METHOD FOR TREATING CYTOKINE MEDIATED HEPATIC INJURY

This application claims the benefit of U.S. application Ser. No. 60/238,991, filed Oct. 10, 2000.

FIELD OF THE INVENTION

The invention relates to the use of compounds to attenuate or prevent cytokine mediated hepatic injury.

BACKGROUND

Hepatic injury can be caused by a number of different agents including viruses such as Hepatitis A, B, C, D and E, both gram positive and gram negative bacteria, chemical agents such as ethanol, carbon tetrachloride and lead, and by physical trauma resulting in ischemia (ischemic hepatitis) injuries as can occur in right-sided congestive heart failure. It is now believed that all of these types of hepatic injury are caused at least in part by the liver's inflammatory or cytokine response to these agents. The inflammatory response of the liver results in the overexpression of a cascade of inflammatory/acute phase cytokines, such as interleukin-1 (IL-1), tumor necrosis factor (TNF), IL-6, IL-8 and transforming growth factor beta (TGF β). It is now believed that it is the cascade of these cytokines which is the ultimate cause of much of the hepatic injury resulting from these agents. Thus, there is a need for a therapeutic agent which can be useful in alleviating or modulating the inflammatory response associated with liver disease or injury.

SUMMARY OF THE INVENTION

The present invention fills this need by providing a method of treating or preventing a cytokine mediated hepatic injury in a mammal comprised of administering a pharmaceutically effective amount of a peptide having the sequence Tyr-D-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-Phe-His-Ser-Ile-NH₂, SEQ ID NO: 1, hereinafter referred to as compound D, to said mammal. The hepatic injury can be an acute inflammatory reaction, as a result of a viral or bacterial infection or a chemical agent such as ethanol, lead, carbon tetrachloride or acetaminophen, or from trauma resulting in ischemia or reperfusion injury in the liver.

The present invention is also directed to a method of treating a viral or bacterial infection-related hepatic damage in a mammal comprised of administering a pharmaceutically effective amount of compound D SEQ ID NO: 1 to said mammal.

The present invention is also directed to a method of treating alcohol induced liver injury in a mammal comprised of administering a pharmaceutically effective amount of compound D SEQ ID NO: 1 to said mammal.

Preferably, compound D SEQ ID NO:1 is administered in a pharmaceutical composition at a dosage of from about 0.5 mg/kg to about 20 mg/kg per body weight of the mammal.

Preferably, the mammal is a human.

DETAILED DESCRIPTION

A compound used to treat cytokine-mediated hepatic injury is a peptide having the sequence Tyr-D-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-Phe-His-Ser-Ile-NH₂ SEQ ID NO:1, hereinafter referred to compound-D. The peptide may be produced by a number of methods, such as using an automated peptide synthesizer, through recombinant molecular techniques, or isolated from a naturally occurring source, as is known to one skilled in the art. Compound-D SEQ ID NO:1 has a molecular weight of 1,902 daltons. Compound-D SEQ ID NO:1 is insoluble in water or saline, but may be solubilized by adding 100 μ M of a solution comprised of ethanol, propylene glycol, and 1 N NaOH in a 1:1:1 ratio, with sterile physiological saline then used to obtain the appropriate concentration. The initial alkaline pH is adjusted to 7.4 with 1 N HCl.

Compound-D SEQ ID NO:1 that has been solubilized may be administered by parenteral means, for example, by intravenous injection. For administration into a mammal, a dose of about 1-20 milligrams per kilogram (mg/kg) is useful. For administration into a tissue or organ preservation solution, a concentration of about 100 μ M is useful.

2

Compound-D SEQ ID NO:1 may be administered directly into a mammal, either alone or in combination with other substances.

The above agent is administered to a mammal to modulate cytokine activation by blocking one or more steps in the cytokine cascade. The agent may be formulated for administration in an aqueous based liquid such as phosphate buffered saline to form an emulsion, or may be formulated in an organic liquid such as dimethylsulfoxide to form a solution. The solution or emulsion may be administered by any route, but it is preferably administered parenterally such as by intravenous, intramuscular, intradermal or intraperitoneal injections. A preferred dose is in the range of about 0.5–20 mg of compound-D SEQ ID NO:1 per kg of body weight of the mammal. The time of administration of the agent is preferably prior to initiation of cytokine activation. However, the agent may be administered concurrently with another agent that induces cytokine activation or even subsequent to an agent that induces cytokine activation and still produce a protective effect.

Administration of compound-D SEQ ID NO:1 should be continued on a daily basis until hepatic function returns to normal and is maintained at normal levels, preferably for at least one to two days. Hepatic injury can be determined by elevated levels of hepatic enzymes, as well as by depressed albumin levels (less than about 35 g/liter). Hepatic function is routinely monitored by quantitating serum levels of hepatic enzymes such as alanine aminotransferase (ALT) (normal < 35 U/L), aspartate aminotransferase (AST) (normal < 30 U/L), alkaline phosphatase (ALP) (normal \leq 100 U/L) and gamma glutamyltransferase (GGT) (normal \leq 45 U/L for males, \leq 30 U/L for females), as well as bilirubin, both conjugated (normal \leq 0.2 mg/deciliter) and total (normal \leq 1.0 mg/deciliter) bilirubin. Compound-D SEQ ID NO:1 modulation of hepatocyte cytokine activation may be used therapeutically in a variety of hepatic injury processes. As used herein, the term hepatic injury broadly encompasses all types of injury such as hepatic trauma, physical and/or chemical insult, stress, inflammation, toxicity, disease and so on. For example, the inventive agents can be used in treating hepatic injury due to alcoholic liver disease, acetaminophen toxicity, cadmium toxicity, lead poisoning, bacteremia due to, for example, *Staphylococcus* species, *Streptococcus* species, *Neisseria* species, *Salmonella* species, *Shigella* species, *Escherichia coli*, *Clostridium perfringens*, *Klebsiella* species, *Proteus* species, *Enterobacter* species, *Bacteroides* species, *Brucella* species, *Francisella tularensis*, *Listeria monocytogenes*, *Acinetobacter* species, *Streptobacillus moniliformis*, *Vibrio* species, *Helicobacter pylori*, *Pseudomonas* species, *Haemophilus* species, *Bordetella pertussis*, viral infections due to, for example, influenza viruses, adenoviruses, paramyxoviruses, rubella viruses, polioviruses, hepatitis viruses, herpesviruses, rabies viruses, human immunodeficiency viruses and papilloma viruses, as well as trauma, ischemia reperfusion injury and metabolic liver disease.

While the specific mechanism of action of compound-D SEQ ID NO:1 on the modulation of cytokine mediated hepatic injury such as acute inflammatory reactions, trauma and toxin induced biological responses is unknown, these agents exhibit a specific and reproducible effect on decreasing hepatotoxicity.

A treatment for attenuating and/or preventing cytokine mediated acute inflammatory, trauma induced and toxin induced hepatic injury is thus disclosed. Compound-D SEQ ID NO:1, administered at a concentration of about 0.5 mg/kg to about 20 mg/kg, inhibits hepatic injury and result in decreased lethality of an injured animal.

It should be understood that the embodiments of the present invention shown and described in the specification are only preferred embodiments of the inventors who are skilled in the art and thus are not limiting in any way. Therefore various changes, modifications or alterations to these embodiments may be made or resorted to without departing from the spirit of the invention and the scope of the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 1
 <210> SEQ ID NO 1
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <221> NAME/KEY: MOD_RES
 <222> LOCATION: (1)..(17)
 <223> OTHER INFORMATION: Xaa = D-Leu; artificial sequence is completely synthesized
 <400> SEQUENCE: 1
 Tyr Xaa Phe Ala Asp Val Ala Ser Thr Ile Gly Asp Phe Phe His Ser Ile
 1 5 10 15

20

What is claimed is:

1. A method for treating a bacterial infection related hepatic injury in a mammal comprising administering a pharmaceutically effective concentration of the peptide shown in SEQ ID NO:1 for a duration to treat hepatic injury related to the bacterial or viral infection.

2. The method of claim 1 wherein the bacterial infection is caused by an organism selected from the group consisting of *Staphylococcus* species, *Streptococcus* species, *Neisseria* species, *Salmonella* species, *Shigella* species, *Escherichia coli*, *Clostridium perfringens*, *Klebsiella* species, *Proteus* species, *Enterobacter* species, *Bacteroides* species, *Brucella* species, *Francisella tularensis*, *Listeria monocytogenes*, *Acinetobacter* species, *Streptobacillus moniliformis*, *Vibrio* species, *Helicobacter pylori*, *Pseudomonas* species, *Haemophilus* species, *Bordetella pertussis*.

3. The method of claim 1 wherein said compound is administered prior to said response.

4. The method of claim 1 wherein said compound is administered subsequent to said response.

5. The method of claim 1 wherein said compound is administered substantially concurrently with said response.

6. The method of claim 1 wherein said compound is administered in the formulation selected from the group consisting of a solution, an emulsion and a suspension.

7. The method of claim 1 wherein said compound is administered parenterally.

8. The method of claim 1 wherein said compound is administered at a concentration in the range of about 0.5 mg/kg to about 20 mg/kg.

9. The method of claim 1 wherein said compound is administered at least until hepatic function normalizes.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,875,742 B2
DATED : April 5, 2005
INVENTOR(S) : Oeltgen et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page.

Item [56], **References Cited**, OTHER PUBLICATIONS,

"Zhao and Bhargava" reference, "brain δ -opioid receptors", should be -- brain δ receptors --.

"Stefano et al." reference, "Internatonal J. Cardiology" should be -- International J. Cardiology --.

"Schultz et al" reference, "is mediated by δ 1-" should be -- is mediated by δ 1- --.

"Oeltgen et al" reference, "agonists for myocardiol ischemia" should be -- agonists for myocardial ischemia --.

Column 3.

Line 26, delete "or viral".

Line 35, "species, Bordetella pertussis" should be -- species, and Bordetella pertussis --.

Signed and Sealed this

Thirtieth Day of August, 2005

A handwritten signature in black ink on a light blue grid background. The signature reads "Jon W. Dudas" in a cursive style.

JON W. DUDAS

Director of the United States Patent and Trademark Office